Tomohide Takaya

This study shows that the anti-nucleolin aptamer iSN04 inhibits alveolar rhabdomyosarcoma cell growth by promoting myogenic differentiation and enhancing the efficacy of vincristine.

This study shows that iSN40, a CpG-ODN, inhibits osteoclast formation via TLR9-dependent mechanisms and may be a therapeutic for osteoporosis.

The paper shows that the anti-nucleolin aptamer iSN04 inhibits vascular smooth muscle cell proliferation and promotes differentiation, suggesting it as a potential therapy for vascular disease.

This paper develops a 12-base myogenetic oligodeoxynucleotide that maintains the myogenic activity of a longer sequence while improving drug efficacy and synthesis cost.